GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Cash Flow from Financing

Vectus Biosystems (ASX:VBS) Cash Flow from Financing : A$-0.09 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Vectus Biosystems paid A$0.00 Mil more to buy back shares than it received from issuing new shares. It received A$0.00 Mil from issuing more debt. It paid A$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received A$0.00 Mil from paying cash dividends to shareholders. It received A$0.00 Mil on other financial activities. In all, Vectus Biosystems spent A$0.00 Mil on financial activities for the six months ended in Dec. 2023.


Vectus Biosystems Cash Flow from Financing Historical Data

The historical data trend for Vectus Biosystems's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Cash Flow from Financing Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Flow from Financing
Get a 7-Day Free Trial 1.04 5.64 6.35 -0.04 4.04

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 4.12 -0.09 -

Vectus Biosystems Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Vectus Biosystems's Cash from Financing for the fiscal year that ended in Jun. 2023 is calculated as:

Vectus Biosystems's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectus Biosystems  (ASX:VBS) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Vectus Biosystems's issuance of stock for the six months ended in Dec. 2023 was A$0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Vectus Biosystems's repurchase of stock for the six months ended in Dec. 2023 was A$0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Vectus Biosystems's net issuance of debt for the six months ended in Dec. 2023 was A$0.00 Mil. Vectus Biosystems received A$0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Vectus Biosystems's net issuance of preferred for the six months ended in Dec. 2023 was A$0.00 Mil. Vectus Biosystems paid A$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Vectus Biosystems's cash flow for dividends for the six months ended in Dec. 2023 was A$0.00 Mil. Vectus Biosystems received A$0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Vectus Biosystems's other financing for the six months ended in Dec. 2023 was A$0.00 Mil. Vectus Biosystems received A$0.00 Mil on other financial activities.


Vectus Biosystems Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems (ASX:VBS) Business Description

Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines